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Abstract
The present knowledge on the androgens role in cardiovascular physiology is not
fully completed. It remains unclear whether low serum testosterone concentrations
in men are an independent risk factor for cardiovascular diseases (CVDs) or a
marker of the presence of CVD. However, we demonstrated that endogenous tes-
tosterone levels may be implicated in CVDs. Androgens role in modulating cardio-
vascular function is one of the highest importances, given that its deficiency is
strongly associated with hypertension, atherosclerosis, diabetes, obesity, and car-
diac hypertrophy. Although significant and independent association between tes-
tosterone levels and cardiovascular events in elderly men have not been confirmed
in large prospective studies, cross-sectional studies, however, suggested that low
testosterone levels in elderly men are associated with CVDs. The results of androgen
therapy are not also conclusive. Perhaps, the effects of testosterone treatment of
cardiovascular mortality and morbidity have not been extensively examined in
control studies. Data on male animal experimentation of the effect of testosterone
replacement therapy are either neutral or beneficial on the development of athero-
sclerosis. Since circulatory androgen levels modulation is expected to cause many
other side effects, it seems to be essential to develop a strategy to target androgen
receptor for better treating the CVDs.
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1. Introduction
Cardiovascular diseases (CVDs) refers to a class of diseases that involve the
heart and/or blood vessels and still the highest leading cause of death in developed
and developing countries with earlier onset and possibly of greater mortality risk
seen in males compared to females. Approximately 17.5 million people died from
CVDs in 2012 representing 31% of all global deaths. It is anticipated that by 2030,
the number of death due to CVDs will be reach to more than 23.6 million [1]. Since
male gender is one of the risk factors for premature coronary artery disease, stroke,
peripheral vascular disease, and heart failure, androgens have often been consid-
ered as a cause underlying this male disadvantage [2, 3]. Androgens, mainly
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testosterone, may also play in cardiovascular morbidity and mortality by modulat-
ing the risk factors of atherosclerosis and vascular functions, lesions to cerebral
and peripheral arterial vessel and myocardial infarction leading to heart failure in
male [4].
A recent perspective study reveals that testosterone levels in men decline
gradually with increasing age and this caused a dramatic increase in the incidence
of CVDs [5, 6], but the mechanism of age-related cardiovascular performance
remains to be completely understood. However, a protective role of androgen for
CVDs in men has been reported and its deficiency may increase the significant risk
factor for CVDs. Moreover, controversy also exists whether this age-associated
decline in testosterone level is a natural physiologic processes or combination of
co-morbidities and life-style choices [7]. With the prospects of much wider thera-
peutic approaches of testosterone on CVDs, it has become increasingly important to
address whether testosterone treatment might increase the risk of severity of CVDs.
Considering the importance of therapeutic use of testosterone as have been
reflected in several recent studies, it is important to address the issue in a more
critical way.
2. Cardiovascular diseases: types and risk factors
CVDs refer to any dysfunctional condition of the heart or the blood vessels
(arteries, veins, and capillaries). Coronary heart disease (CHD) and stroke are two
fundamental components of CVDs [8]. CVDs can be classified in eight major
groups. These are: stroke-disruption of the blood supply to the brain either from
blockage or from rupture of blood vessels; CHD-disease of blood vessels,
transporting blood to the heart muscle; rheumatic heart disease-caused due to
rheumatic fever by streptococcal bacteria when heart muscles and valves are
damaged; congenital heart disease-structural malformation of heart; aortic
aneurysm-dilation and rupture of aorta; peripheral arterial disease-disease of the
arteries that supply blood to arms and legs; deep venous thrombosis and pulmo-
nary embolism-blood clot in leg veins, which can dislodge and move to heart and
brain; and other CVDs- tumors of the heart, vascular tumor of the brain, disorder
of the heart muscle lining etc.
Risk factors can be categorized as modifiable and non-modifiable risk factors.
Modifiable risk factors include; high blood pressure, abnormal blood lipids,
tobacco use, physical inactivity, obesity, unhealthy diets, and diabetes mellitus.
Non-modifiable risk factors are advancing age, hereditary or family history, gender,
and race.
3. Testosterone and its function
Testosterone, a C19 androgen, is the most vital circulating androgens both in
male and female. In men, it is mainly synthesized in the testes and a small amount
is also derived from adrenal cortex. Testosterone is essential for male sexual
differentiation, development and normal function of male reproductive organs,
and maintenance of secondary sexual characters. In addition, testosterone
promotes many other physiological processes like bone formation, growth of mus-
cle, hair growth, body composition, and erythropoiesis and decreased the risk of
osteoporosis [9]. In normal adult men, testosterone concentration ranges between
241 and 827 ng/dl [10]. Secretion of testosterone varies with circadian rhythm.
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Circulating testosterone is mainly bound to sex hormone binding globulin (SHBG)
and albumin and only 1–2% remains as unbound form.
In target cells, testosterone binds to the intracellular androgen receptors (ARs)
or is converted to dihydrotestosterone (DHT) catalyzed by 5α-reductase, which
then binds to AR. In some target tissues, testosterone is converted to estrogens by
cytochrome P450 aromatase enzyme and estrogens then bind to estrogen receptors.
Both androgen and estrogen receptors act as transcription factors and mediate
genomic effects [11]. In addition, various in vitro and in vivo studies have shown
that testosterone and its derivatives can affect cellular processes in a non-genomic
fashion [12]. Testosterone has been shown to regulate cell to cell ion exchange via
gap junction in Sertoli cells and cardiac cells in young rats [13]. Testosterone also
promotes vasoconstriction [14, 15] and rapid rise of Ca2+ in cultured
cardiomyocytes by PLC/IP3-dependent mechanism [16].
4. Circulatory levels of testosterone and CVDs
Association of blood testosterone levels and incidence of CVDs in men with
increasing age is based mainly on observational studies and the main disadvantages
of such type of studies are the extremely variable endpoints of CVDs, heteroge-
neous study groups, and diverse selection criteria. A continuous study for months to
several years on a particular study group of CVD patient is very difficult for various
reasons. Importantly, patients in these study groups are mostly in medications or
modified their life style. Moreover, selection of poorly-matched controls and timing
of blood sampling are not always standardized for diurnal variation of hormone
levels. All these factors have a serious impact to draw a definite conclusion. How-
ever, taking all these into consideration, recently, we investigated the relationship
between serum total testosterone levels and lipid profiles as well as fasting blood
glucose (FBG) levels in elderly men with angiographically confirmed CVDs from
two thickly populated and socio-economically backward districts; Nadia and
Murshidabad of West Bengal, India. We observed that relationship between sex
hormones, lipid profiles and FBG levels of CVD patients is strikingly different from
men with no CVDs of similar age group [17]. Considering the previous observa-
tional studies along with our study, we presented a comprehensive idea on the
relationship between serum testosterone levels and CVDs globally.
In normal men of developed countries, the overall incidence of testosterone
deficiency increases with age and approximately one half a million new cases of
testosterone deficiency are expected in men aged 40–90 years old (Figure 1) [18].
An independent effect of age on serum testosterone in a study of 890 men has also
been demonstrated [19]. Prevalence of testosterone deficiency in men aged >45
years is approximately 38.7% based on total testosterone (T) levels and about 36.3%
based on bio-available or free T [20]. They have documented that major risk factors
such as obesity, diabetes, hypertension, hyperlipidaemia, prostate disease, and
asthma or chronic obstructive pulmonary disease are responsible for low testoster-
one levels in men compared without such conditions. A schematic representation
of the association of testosterone and cardiovascular risk factors is depicted in
Figure 2. It has been reported that low testosterone levels are associated with
increased death from CVDs [21]. Whereas, for a long time prospective studies failed
to find significant association between testosterone levels and risk of cardiovascular
events in middle aged men [22, 23]. However, a study of osteoporotic fractures in
elderly men of Sweden reported that high serum testosterone level is associated
with reduced risk of cardiovascular events [24]. This is consistent with the influ-
ence of testosterone levels on multiple risk factors such as obesity, diabetes, blood
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pressure, and carotid atherosclerosis [25, 26]. A recent meta-analysis showed that
low testosterone levels predicted risk for CVDs in elderly men but not middle-aged
men [27]. Interestingly, using data from the French Three-City prospective cohort
study (3650 men aged >65 years) after adjustment for cardiovascular risk factors, a
J-shaped association between plasma total testosterone and incidence of ischemic
arterial disease (IAD) in elderly men has been reported [28]. They have suggested
that both high and low plasma testosterone levels are associated with an increased
risk of arterial ischemic events in elderly men and an optimal range of testosterone
levels may confer protection against cardiovascular events. In a recent study, Kelly
and Jones [29] observed that testosterone replacement in men diagnosed with
hypogonadism shown to be a beneficial effect on several cardiovascular risk factors,
cardiac ischemia, functional exercise capacity, and mortality.
Figure 1.
Testosterone levels in men at different ages of life.
Figure 2.
Association of testosterone deficiency and cardiovascular risk factors.
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5. Association of various risk factors with CVD
5.1 Role of lipids in CVD
It has long been established that lipids play a central role in the initiation and
progression of CVDs [30–32]. Dyslipidemia comprises the abnormalities of lipid
profiles characterized by high levels of total cholesterol (TC), triglyceride (TG), low
density lipoprotein (LDL), and very low density lipoprotein (VLDL) along with low
levels of high density lipoprotein (HDL) that contributes to the development of
atherosclerosis [33]. In older men, reduced testosterone levels are associated with
adverse profiles of lipids. Low testosterone level is associated with high TC, high
LDL [34, 35], and high TG [36, 37]. Hypo-gonadal men exhibit abdominal or central
adiposity [38, 39]. This finding has led to conclude that all parameters of lipid
profile except HDLmight be more strongly associated with CVD risk, whereas some
investigators reported a negative correlation between HDL and CVD [40, 41]. A
strong inverse correlation between body fat and testosterone level is also observed
[42]. Higher mass of visceral adipose tissue is inversely correlated with bio-available
testosterone [43]. In an epidemiological study from our laboratory, we studied the
relationship between serum total testosterone levels and lipid profiles in male
patients ranging the age group between 40 and 70 years with angiographically
proven CVDs from Nadia and Murshidabad district of West Bengal, India and
compared the data with normal men with no CVD history. We observed a signifi-
cantly low serum total testosterone levels in CVD patient group compared to nor-
mal group and further demonstrated a significant negative association between
serum total testosterone and TC, TG, LDL, and VLDL among CVDs patients. How-
ever, a significant positive correlation between serum total testosterone and HDL
was observed [17]. Thus, in these two districts of West Bengal, low levels of serum
total testosterone in elderly men are associated with CVD that appear together with
an atherogenic lipid milieu that may be involved in pathogenesis of CVD. The
molecular mechanism of sex hormone-induced changes in the serum lipid profile is
incompletely understood [33]. However, there are evidence from animals, cell, and
clinical studies that testosterone controls the expression of important regulatory
protein involved in lipid and cholesterol metabolism namely, apolipoprotein A-1
Figure 3.
Changes in lipid profile due to androgen deficiency, leading to atherosclerosis.
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(apoA1) [44, 45], and scavenger receptor class B type 1 (SRB1) [46–48]. The major
component of HDL is apoA1, which is secreted by the liver in lipid free or minimally
lipidated form [44]. The interaction between apoA1 and lipid transfer ABCA1
present in the peripheral tissues results in the formation of minimally lipidated
apoA1, which through a series of steps is converted to discoid shaped pre-HDL. This
does not possess atheroprotective properties [45]. In addition to apoA1 and SRB1,
lipoprotein modifying enzymes are also critical in maintenance of serum lipid
homeostasis. One of the most important lipoprotein modifying enzymes is lipopro-
tein lipase (LPL), present on the endothelial cell surface [49]. Other enzymes are
lecithin-cholesterol-acyl-transferase (LCAT) which esterifies the free cholesterol of
HDL and cholesterol ester transferase protein (CETP), which mediates the
exchange of cholesterol ester between HDL and LDL [44]. Testosterone might
promote the expression of SRB1 receptor and facilitate the selective uptake of HDL,
thereby exerting an antiatherogenic role [50]. A schematic association of testoster-
one deficiency and atherogenic lipid profile is depicted in Figure 3.
6. Relationship between low testosterone levels and cardiovascular
risk factors
6.1 Role of androgens in hypertension
Hypertension is one of the major risk factors for developing CVDs leading to
atherosclerosis and sudden cardiac death. Studies with human reveal that hyperten-
sion is more prevalent and occurs earlier in men than in women [51, 52]. Sexual
dimorphism in blood pressure develops and is maintained until the age of 60 years
[53–55]. Epidemiological data further indicate that women older than 60 years, show
gradual increase in systolic blood pressure over a period of 5–20 years, until hyper-
tension is highly prevalent in women as in men [55–57]. In hypertensive patients,
treatment with antihypertensive drugs can reduce sexual activity and blood concen-
trations of testosterone [58, 59]. However, treatment of androgen to such patients
found to exacerbate hypertension and increase the risk of CVDs [60–62]. There is also
higher incidence of hypertension in individual with reduced free testosterone [63].
In animal studies, all major mouse and rat models (noncastrated, castrated, and
anti-androgen treated) potential role for androgen in the pathogenesis of hyperten-
sion have been documented [55, 64]. In mice, castration and subsequent treatment
with testosterone at high dose produce the onset of hypertension and further
observed that this effect is mediated by androgen receptor [65]. Long back, it was
found that tfm X chromosome (including a mutated non-functional AR) rats and
castrated rats have lower blood pressure than intact control rats, suggesting that
androgen/AR signaling pathway might be involved in hypertension [66]. Thus,
androgen-AR signaling pathway appears to be involved in the regulation of hyper-
tension in men and as androgen level reduce with increasing age this might have a
deleterious effect on the development of hypertension. Antiandrogen treatment
might be able to suppress hypertension. Moreover, some recent studies using AR
knockout mice in selective cells suggest that AR in individual cell types may have
independent role in the development of hypertension [67, 68].
6.2 Testosterone association in type 2 diabetes and insulin resistance,
a risk factor of CVD
Low level of testosterone is associated with type 2 diabetes mellitus (T2DM)
irrespective of age, race, and obesity [69–72]. High plasma testosterone level is
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associated with reduced risk of developing T2DM [73]. Insulin resistance is the most
common hyperglycemic condition and hallmark of T2DM [74]. It is a state where
target cells are not responding to normal levels of circulating insulin leading to
development of T2DM [75, 76]. An inverse relationship between total testosterone
concentration and insulin resistance has also been reported in men [77, 78]. Clinical
trials have demonstrated that testosterone administration improved insulin sensi-
tivity, reduced glycaemia, and heart failure progression in men [79].
Cohort studies from Farmingham, Heart Study, EMAS, and Osteoporotic
Fractures in Men study [80] and Western Australian Health in Men Study [81]
reported that men with T2DM have lower testosterone levels compared with
men without T2DM. In fact, different earlier studies showed that men with T2DM
have 30–40% lower circulatory testosterone levels than that of healthy men
[82–84]. In a study of 3156 men from various ethnic backgrounds, aged 45–84
years and after adjusting for age, ethnicity, BMI, it has been shown that T2DM
and FBG levels are inversely associated with total testosterone concentration [70].
In a recent study with elderly male patients (40–70 years of age) of two district
of West Bengal, we observed a highly significant negative correlation between
serum total testosterone and FBG levels in CVD patients compared with non-CVD
patients of same locality [17]. Our results further indicate that low levels of
serum total testosterone might have role in the development of hyperglycemia as
evidenced from high FBG levels in elderly men. Moreover, a recent study demon-
strated that insulin resistance, hyperinsulinemia, and associated hyperglycemia
can promote the development of specific form of cardio-morphopathy, which is
independent of coronary artery disease and hypertension and a major cause of
morbidity and mortality in developed countries [85]. It is characterized by
myocardial insulin signaling, mitochondrial dysfunction, activation of sympa-
thetic nervous system, activation of renin-angiotensin-aldosterone system, and
male adaptive immune responses [86]. These patho-physiological changes result
in oxidative stress, fibrosis, hypertrophy, cardiac diastolic dysfunction, and
eventually systemic heart failure [87].
Association of testosterone deficiency with hyperglycemia has also been
observed in animal model [88]. It has been demonstrated that castration-induced
testosterone deficiency not only enhanced the hepatic gluconeogenesis but also
decreased extra-hepatic insulin sensitivity in aged male rats [89]. Unpublished
data from our laboratory also demonstrate that castration in adult male mice is
followed by an increase in FBG level compared to sham operated control
group and this increase in serum FBG levels was reversed after treatment with
testosterone.
The mechanism linking androgen with T2DM and insulin receptor is not fully
understood. Testosterone administration up-regulate the expression of GLUT-4,
insulin receptor substrate-1 (IRS-1) in cultured adipocytes, and skeletal muscle cells
[90]. Another study showed that testosterone promotes AKT and PKC phosphory-
lation, the major mediator of insulin receptor signaling, which regulate GLUT-4
translocation (Figure 4) [91]. The beneficial effects of testosterone on diabetes
through increasing the metabolic rate in muscle promoting gain of energy from
adipose tissue resulting decreased fat mass concentration has also been reported
[92]. In vitro study of murine model also demonstrated that testosterone adminis-
tration reduces β cell apoptosis [93], whereas, testosterone deficiency promote
elevation of the expression of RBP4, which increases insulin resistance [94]. On the
contrary, several studies demonstrate a non-positive correlation between testoster-
one supplementation and heart failure. Several clinical trials led to propose that
testosterone supplementation at physiological doses could be a treatment for men
with metabolic syndrome and heart failure [95].
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6.3 Testosterone and vascular inflammation
It is now well accepted that atherosclerosis is a chronic inflammatory disease.
Individuals with hyperlipidaemia and signs of systemic inflammation develop ath-
erosclerosis, with specific defects in lipid processing and immune activity conse-
quentially occurring at the vessel wall. It is known that the activation of endothelial
cells promotes the adhesion of leukocytes to the blood vessel wall as an early
atherogenic event leading to increased vascular permeability for not only the
inflammatory leukocytes, but also the circulating lipid components, such as LDL
[96]. It has been suggested from observational studies that many pro-inflammatory
cytokines like interleukin 1β (IL-1β), IL 6, TNF-α, C-reactive protein (CRP), and
serum testosterone levels are inversely related in patients with CVDs and T2DM
[97–99]. These inflammatory cytokines are known to modulate lipid metabolism,
endothelial functions, and atherosclerosis [100]. Testosterone has been reported to
reduce the levels of TNF-α and elevated circulating anti-inflammatory IL-10
[101, 102] and circulating CRP [102] in hypogonadal men with CVDs. In vitro
studies also support the protective effect of testosterone supplementation on ath-
erosclerosis, but the mechanism is not fully known [103, 104].
7. Testosterone deficiency and vascular functions
A negative correlation between testosterone and hypertension has already been
discussed. In a subpopulation study of 206 aged males, it was shown that serum
testosterone level is an independent negative predictor for developing arterial
Figure 4.
Proposed mechanism of action of testosterone on cellular IRS activation leading to glucose homeostasis.
Testosterone increases GLUT4 expression and membrane translocation which increases cellular uptake and
utilization of glucose. Abbreviations: GLUT4, glucose transporter 4; G6P, glucose-6-phosphate; HK2,
hexokinase 2; IRS, insulin receptor substrate; T +ve indicates targets or activity increased by testosterone PKC
and AKT.
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stiffness and this association remained after adjusting for the other risk factors
[105]. Carotid-intima media thickness (IMT) is a marker for CVDs [106]. The
relationship among the progression of carotid-IMT, atherosclerotic plaque forma-
tion, and total testosterone was investigated and an inverse relationship between
this hormone and atherosclerotic plaque formation was observed. This study also
reported for a positive co-relation between carotid-IMT and atherosclerosis [107].
Men with low serum testosterone level exhibit higher IMT compared to normal
control [108–110]. Long term testosterone administration reduced carotid-IMT in
men with CVDs [111, 112]. Animal models also demonstrated that castration or
hypogonadism in mice or rabbits fed a pro-artherogenic diet results in increased
atherosclerosis and testosterone supplementation inhibits plaque formation [113].
The cellular and molecular mechanism by which testosterone induced IMT is little
understood. Other studies, however, have shown that testosterone may reduce IMT
by down regulating the inflammatory response or acting as a regulator of apoptosis
or increasing vascular smooth muscle cell stability [7].
Endothelial cells play an important role in atherosclerosis, regulation of vascular
tone and forming a barrier that regulates the uptake of cells and macromolecules
into the vessel wall [114]. Clinical evidence suggests a link between testosterone
deficiency and endothelial dysfunction [115–117]. Flow-mediated dilation (FMD),
which represents endothelial dysfunction is decreased in men with testosterone
deficiency and increased after exogenous administration of the steroid [118, 119].
Testosterone can exert direct effects on various cells of vascular wall by activation
of androgen receptor or by non-genomic effects on plasma-membrane receptors
and channels [114]. Testosterone can modulate calcium flux by mechanism that is
independent of androgen and estrogen receptors in macrophages and endothelial
cells [120]. Androgen receptors are expressed in endothelial cells, smooth muscle
cells, and cardiomyocytes and all of these are relevant to atherosclerosis and heart
failure [121]. It has also been demonstrated that testosterone may improve endo-
thelial function through modulation of nitric oxide (NO) release. Endothelium-
produced NO plays a variety of roles in vascular function maintenance like vasodi-
latation, inhibition of cell death, and platelet aggregation [96, 122].
8. Role of androgens in cardiac hypertrophy
Cardiac growth can be divided into two categories: normal growth in the devel-
opmental process and cardiac hypertrophy induced by hemodynamic overload.
Since cardiomyocytes are terminally differentiated and lost their ability to multiply
soon after birth, they respond to increased workload by an increase in cell size
(hypertrophy), not by an increase in cell number (hyperplasia). Cardiac hypertro-
phy is prevalent in men with hypertension and recognized as an independent risk
factor for congestive heart failure and sudden cardiac death [123]. The most
impressive evidence of the effect of androgens on heart is the case of highly condi-
tioned athletes, who died by sudden cardiac death. Examination of such death
indicated anatomical abnormalities in heart, known as hypertrophy-cardiac myop-
athy [124]. Since, the net weight of heart is increased as a result of individual
cardio-myocyte, the cardiac hypertrophy is assessed as heart weight to body weight
ratio and left ventricular hypertrophy (LVH). LVH is the most potent predictor of
adverse cardiovascular outcomes in hypertensive populations and is independent
risk factors for coronary heart disease, sudden death, heart failure, and stroke.
Clinically LVH is diagnosed by evaluating ventricular functions, such as left ven-
tricular ejection fraction, left ventricular shortening fraction, end-systolic, and end-
diastolic volume by electro physiological studies. Although directly related to
9
Role of Androgens in Cardiovascular Diseases in Men: A Comprehensive Review
DOI: http://dx.doi.org/10.5772/intechopen.85852
systolic blood pressure, other factors including age, sex, race, body mass index, and
stimulation of renin-angiotensin-aldosterone system and sympathetic nervous sys-
tem play an important role of pathogenesis of LVH. LVH is associated both with
hypertension and increased cardiovascular morbidity and mortality [125], and it has
been suggested that testosterone could be influential in modulating left ventricular
mass [126]. Low level of testosterone in male is associated with high blood pressure
and left ventricular mass [127]. Interestingly, this association is mediated through
obesity. Very recently, it has also been suggested that testosterone can induce
hypertrophy in rat heart, which is independent of exposure duration [128].
A central link for the development of skeletal muscle hypertrophy is the activa-
tion of mammalian target of rapamycin (mTOR) [129, 130], which also have been
reported in testosterone-induced cardiomyocyte hypertrophy [131]. Both type I and
type II skeletal muscle fibers have shown to respond in testosterone treatment
increasing muscle mass, cross-sectional areas (CSA), and satellite cell number after
hormone administration [132]. Testosterone and its synthetic cognates have been
used both clinically and illicitly to increase muscle mass [133]. However, the cellular
mechanism explaining these effects is not completely understood. Different cellular
and molecular mechanisms are shown to be involved in skeletal muscle hypertrophy
induced by testosterone, including promotion of nuclear accretion, entry of satellite
cells into cell cycle [132–134], and activation of intracellular androgen receptor
[135]. Besides regulating gene expression via AR, testosterone also produces fast,
non-transcriptional responses involving membrane-linked signal transduction
pathways [12]. A rapid non-genomic action exerted via G-protein coupled receptor,
intracellular calcium increases, and extracellular signal regulated kinase ½ (ERK
1/2) activation has been described for the action of testosterone in skeletal
myotubes [136]. Recently, a cellular lineage of myoblast, which lack the classical AR
(L6 myoblast), testosterone has shown to promote the proliferation and differenti-
ation of L6 cell via G-protein coupled receptor [137]. Altogether, these data suggest
that in men testosterone, increased cardiac hypertrophy and aside from classical
mechanism of action of testosterone, non-classical actions are also implicated in
development of cardiac hypertrophy.
9. Testosterone replacement therapy in CVD patients
Testosterone replacement therapy (TRT) is increasingly promoted and suggested
to be a possible curative way for the adverse effect of low testosterone on CVDs in
elderly men.Whereas, the effectiveness of TRT in hypogonadal men has been shown
to be effective in alleviating the symptoms of fatigue, sexual dysfunction, depression,
decreased bone density, decreased muscle mass, among others [138–141], uncer-
tainties remain with respect to cardiovascular safety for its use. In 2004, a committee
on assessing the need for clinical trial of testosterone replacement therapy by Insti-
tute of Medicine (IOM) in a review concluded largely based on placebo control trials
and show that there is no clear evidence on benefit of the heath outcome examined.
In fact, no positive effect of TRT on cardiovascular events was observed [142–144].
Observational studies evaluating the cardiovascular safety of TRT in men have also
generated inconsistent results [145, 146]. An independent review conducted by
European Medicines Agency (EMA) also found a lack of consistent evidence for TRT
increasing cardiovascular risks (European Medicines Agency (EMA)), 2015 [147].
Very recently, in systematically review and meta-analysis by various authors did not
find any significant association between exogeneous testosterone treatment and
myocardial infarction, stroke or morbidity of randomized control trials [148, 149].
But, a recent study demonstrated that testosterone treatment in men with low
10
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endogenous testosterone shows improved survival rate in CVD patients [150]. Phys-
iological replacement of testosterone has been shown to decrease cholesterol level
and LDL concentration in men [101, 151]. Studies on the effect of TRT on HDL
concentration yielded conflicting result with either a decrease [152] or no changes
[102, 153]. Other investigators observed an increase in concentration of HDL level
after testosterone administration [154]. In a recent study on the effects of TRT on
lipid metabolism in hypogonadal men with T2DM, it has been hypothesized that
because the relationship between lipid metabolism and artherosclerosis are unequiv-
ocal, TRT, which ameliorates lipid metabolism, may decrease the morbidity and
mortality of CVD in hypogonadal men with T2DM by preventing atherogenesis
[155]. Data from randomized placebo-controlled trials (RCTs) suggest that treatment
with testosterone is not effective in reducing CV risk; however, when TRT is cor-
rectly applied, it is not associated with an increase in CV risk and it may have
beneficial effects in sub-population [156]. On the contrary, available reports indi-
cated that TRT is positively correlated with increased cardiovascular risk [157]. It has
been reported that those who are under TRT showed increased risk of CVDs
[158, 159]. A systemic review and meta-analysis of the effect of testosterone therapy
on cardiovascular events showed that testosterone increases cardiovascular related
events among men. The risk of TRT was particularly marked in trials [160].
10. Effects of testosterone on myocardial infarction
The myocardial cells undergo a dynamic repair process after myocardial infarc-
tion (MI), which is also regulated by hormonal factors and characterized by removal
of necrotic tissue and chamber dilatation for so-called “cardiac remodeling” [161].
Recent cohort studies and meta-analyses of randomized clinical trials reported that
testosterone therapy is associated with an increased risk of MI, ischemic stroke, and
overall mortality [157, 159]. Supplemental testosterone treatment dramatically
increased cardiac rupture and mortality in female mice with or without ovariec-
tomy, whereas castration significantly decreased both the events in males [160].
This indicates role of testosterone is sex specific and even hypotesteronemic condi-
tion is good for MI associated cardiac remodeling. Findings suggest that testosterone
may adversely affect myocardial healing and early remodeling during the acute
phase of MI, causing the observed “gender difference.” However, this is highly
controversial and association between testosterone therapies and cardiovascular
disease is complex and need more dose-specific and time-specific statistical analyses
and molecular studies to conclude that whether TRT is beneficial or not.
11. Conclusion
For last two decades, androgens have attracted significant interest in explaining
the gender difference in CVDs. Although, strong evidences show that testosterone
is associated with prevalence of CVDs and affects several key cardiovascular risk
factors and increase the risk of cardiovascular mortality, significant independent
association between androgen levels and cardiovascular events in men have not
been confirmed in large prospective studies. Effects of testosterone therapy on
cardiovascular mortality have not also been definitely confirmed in prospective
controlled studies. Testosterone administration in men and animal induces both
beneficial and deleterious effects on cardiovascular risk factors. Further research in
this field is necessary to know the real cardiovascular effects of androgen and to
understand the role of androgen in therapeutic applications in CVDs.
11
Role of Androgens in Cardiovascular Diseases in Men: A Comprehensive Review
DOI: http://dx.doi.org/10.5772/intechopen.85852
Author details
Dilip Mukherjee*, Koushik Sen, Shreyasi Gupta, Piyali Chowdhury,
Suravi Majumder and Payel Guha
Department of Zoology, Kalyani University, Nadia, West Bengal, India
*Address all correspondence to: dilipmukher@rediffmail.com
©2020TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
12
Chemistry and Biological Activity of Steroids
References
[1]Mozaffarian D, Benjamin EJ, Go AS,
Arnett DK, Blaha MJ, Cushman M, et al.
Heart disease and stroke statistics—
2016 update: A report from the
American Heart Association.
Circulation. 2015;1:CIR350
[2] Kaufman JM, Vermeulen A. The
decline of androgen levels in elderly
men and its clinical and therapeutic
implications. Endocrine Reviews. 2005;
26(6):833-876
[3] Banos G, Guarner V, Perez-Torres I.
Sex steroid hormones, cardiovascular
diseases and the metabolic syndrome.
Cardiovascular & Hematological Agents




[4] Snyder PJ, Bhasin S,
Cunningham GR, Matsumoto AM,
Stephens-Shields AJ, Cauley JA, et al.
Effects of testosterone treatment in
older men. New England Journal of
Medicine. 2016;374(7):611-624
[5] Lakatta EG, Levy D. Arterial and
cardiac aging: Major shareholders in
cardiovascular disease enterprises: Part
I: Aging arteries: A “set up” for vascular
disease. Circulation. 2003;107(1):
139-146
[6] Ayaz O, Howlett SE. Testosterone
modulates cardiac contraction and
calcium homeostasis: Cellular and
molecular mechanisms. Biology of Sex
Differences. 2015;6(1):9. DOI: 10.1186/
s13293-015-0027-9
[7]Oskui PM, French WJ, Herring MJ,
Mayeda GS, Burstein S, Kloner RA.
Testosterone and the cardiovascular
system: A comprehensive review of the
clinical literature. Journal of the
American Heart Association. 2013;2(6):
e000272
[8]Mackay J. The atlas of heart disease
and stroke. World Health Organization.
2004:18-25
[9]Matsumoto AM, Bremner WJ.
Testicular disorders. In: Melmed S,
Polonsky K, Larsen P, Kronenberg,
editors. Williams Textbook of
Endocrinology. 12th ed. Philadelphia:
Elsevier; 2011. pp. 689-777
[10] Seth M, Sachdeva A, Sahary P,
Seth S, Madaan H. Relationship of
testosterone levels in males with
coronary heart disease. International
Journal of Pharmacology and
Biosciences. 2011;2(2):B-566-B-570
[11] Falkenstein E, Tillmann HC,
Christ M, Feuring M, Wehling M.
Multiple actions of steroid hormones—
A focus on rapid, nongenomic effects.
Pharmacological Reviews. 2000;52(4):
513-556
[12] Foradori CD, Weiser MJ, Handa RJ.
Non-genomic actions of androgens.
Frontiers in Neuroendocrinology. 2008;
29(2):169-181
[13] Pluciennik F, Verrecchia F,
Bastide B, Herve JC, Joffre M, Deleze J.
Reversible interruption of gap
junctional communication by
testosterone propionate in cultured
Sertoli cells and cardiac myocytes. The
Journal of Membrane Biology. 1996;
149(3):169-177
[14]Masuda A, Mathur R, Halushka PV.
Testosterone increases thromboxane A2
receptors in cultured rat aortic smooth
muscle cells. Circulation Research. 1991;
69(3):638-643
[15] Schrör K, Morinelli TA, Masuda A,
Matsuda K, Mathur RS, Halushka PV.
Testosterone treatment enhances
thromboxane A2 mimetic induced
coronary artery vasoconstriction in
13
Role of Androgens in Cardiovascular Diseases in Men: A Comprehensive Review
DOI: http://dx.doi.org/10.5772/intechopen.85852
guinea pigs. European Journal of Clinical
Investigation. 1994;24(S1):50-52
[16] Vicencio JM, Ibarra C, Estrada M,
Chiong M, Soto D, Parra V, et al.
Testosterone induces an intracellular
calcium increase by a nongenomic
mechanism in cultured rat cardiac
myocytes. Endocrinology. 2006;147(3):
1386-1395
[17] Chowdhury P, Sen K, Gupta S,
Majumder S, Guha P, Chakraborty A,
et al. Association of endogenous
testosterone with lipid and blood
glucose profiles in elderly men with
angiographically proven cardiovascular
disease of Nadia and Murshidabad
District, West Bengal. Proceedings of
the Zoological Society. Springer Nature.
2018;71:48-55
[18] Araujo AB, O’donnell AB,
Brambilla DJ, Simpson WB,
Longcope C, Matsumoto AM, et al.
Prevalence and incidence of androgen
deficiency in middle-aged and older
men: Estimates from the Massachusetts
Male Aging Study. The Journal of
Clinical Endocrinology & Metabolism.
2004;89(12):5920-5926
[19]Harman SM, Metter EJ, Tobin JD,
Pearson J, Blackman MR. Longitudinal
effects of aging on serum total and free
testosterone levels in healthy men. The
Journal of Clinical Endocrinology &
Metabolism. 2001;86(2):724-731
[20]Mulligan K, Zackin R, Von
Roenn JH, Chesney MA, Egorin MJ,
Sattler FR, et al. Testosterone
supplementation of megestrol therapy
does not enhance lean tissue accrual in
men with human immunodeficiency
virus-associated weight loss: A
randomized, double-blind, placebo-
controlled, multicenter trial. The Journal
of Clinical Endocrinology &
Metabolism. 2006;92(2):563-570
[21]Hyde Z, Norman PE, Flicker L,
Hankey GJ, Almeida OP, McCaul KA,
et al. Low free testosterone predicts
mortality from cardiovascular disease
but not other causes: The Health in Men
Study. The Journal of Clinical
Endocrinology & Metabolism. 2012;
97(1):179-189
[22] Yarnell JW, Beswick AD,
Sweetnam PM, Riad-Fahmy D.
Endogenous sex hormones and ischemic
heart disease in men. The Caerphilly
prospective study. Arteriosclerosis,
Thrombosis, and Vascular Biology.
1993;13(4):517-520
[23] Ärnlöv J, Pencina MJ, Amin S,
Nam BH, Benjamin EJ, Murabito JM,
et al. Endogenous sex hormones and
cardiovascular disease incidence in men.
Annals of Internal Medicine. 2006;
145(3):176-184
[24]Ohlsson C, Barrett-Connor E,
Bhasin S, Orwoll E, Labrie F,
Karlsson MK, et al. High serum
testosterone is associated with reduced
risk of cardiovascular events in elderly
men: The MrOS (Osteoporotic Fractures
in Men) study in Sweden. Journal of the
American College of Cardiology. 2011;
58(16):1674-1681
[25] Yeap BB. Are declining testosterone
levels a major risk factor for ill-health in
aging men? International Journal of
Impotence Research. 2009;21(1):24-36
[26] Soisson V, Brailly-Tabard S,
Empana JP, Féart C, Ryan J, Bertrand M,
et al. Low plasma testosterone and
elevated carotid intima-media thickness:
Importance of low-grade inflammation
in elderly men. Atherosclerosis. 2012;
223(1):244-249
[27] Ruige JB, Mahmoud AM, De
Bacquer D, Kaufman JM. Endogenous
testosterone and cardiovascular disease
in healthy men: A meta-analysis. Heart.
2011;97(11):870-875
[28] Soisson V, Brailly-Tabard S,
Helmer C, Rouaud O, Ancelin ML,
14
Chemistry and Biological Activity of Steroids
Zerhouni C, et al. A J-shaped association
between plasma testosterone and risk of
ischemic arterial event in elderly men:
The French 3C cohort study. Maturitas.
2013;75(3):282-288
[29] Kelly DM, Jones TH. Testosterone
and cardiovascular risk in men. In:
Cardiovascular Issues in Endocrinology.
Vol. 43. Basel, Switzerland: Karger
Publishers; 2014. pp. 1-20
[30] Ginsberg HN. Lipoprotein
metabolism and its relationship to
atherosclerosis. The Medical Clinics of
North America. 1994;78(1):1-20
[31] Glew RH, Kassam HA, Bhanji RA,
Okorodudu A, VanderJagt DJ. Serum
lipid profiles and risk of cardiovascular
disease in three different male
populations in northern Nigeria. Journal
of Health, Population and Nutrition.
2002;1:166-174
[32] Chrysohoou C, Panagiotakos DB,
Pitsavos C, Kosma K, Barbetseas J,
Karagiorga M, et al. Distribution of
serum lipids and lipoproteins in patients
with beta thalassaemia major; an
epidemiological study in young adults
from Greece. Lipids in Health and
Disease. 2004;3(1):3
[33] Traish AM, Abdou R, Kypreos KE.
Androgen deficiency and
atherosclerosis: The lipid link. Vascular
Pharmacology. 2009;51(5-6):303-313
[34] Simon D, Charles MA, Nahoul K,
Orssaud G, Kremski J, Hully V, et al.
Association between plasma total
testosterone and cardiovascular risk
factors in healthy adult men: The
Telecom Study. The Journal of Clinical
Endocrinology & Metabolism. 1997;
82(2):682-685
[35] Barud W, Palusiński R, Bełtowski J,
Wójcicka G. Inverse relationship
between total testosterone and anti-
oxidized low density lipoprotein
antibody levels in ageing males.
Atherosclerosis. 2002;164(2):283-288
[36]Mäkinen JI, Perheentupa A, Irjala K,
Pöllänen P, Mäkinen J, Huhtaniemi I,
et al. Endogenous testosterone and
serum lipids in middle-aged men.
Atherosclerosis. 2008;197(2):688-693
[37] Akishita M, Fukai S, Hashimoto M,
Kameyama Y, Nomura K, Nakamura T,
et al. Association of low testosterone
with metabolic syndrome and its
components in middle-aged Japanese
men. Hypertension Research. 2010;
33(6):587
[38]Haffner SM, Mykkänen L,
Valdez RA, Katz MS. Relationship of sex
hormones to lipids and lipoproteins in
nondiabetic men. The Journal of Clinical
Endocrinology & Metabolism. 1993;
77(6):1610-1615
[39] Couillard C, Gagnon J, Bergeron J,
Leon AS, Rao DC, Skinner JS, et al.
Contribution of body fatness and
adipose tissue distribution to the age
variation in plasma steroid hormone
concentrations in men: The HERITAGE
Family Study 1. The Journal of Clinical
Endocrinology & Metabolism. 2000;
85(3):1026-1031
[40]Gordon DJ, Probstfield JL,
Garrison RJ, Neaton JD, Castelli WP,
Knoke JD, et al. High-density
lipoprotein cholesterol and
cardiovascular disease. Four prospective
American studies. Circulation. 1989;
79(1):8-15
[41] Barter P, Gotto AM, LaRosa JC,
Maroni J, Szarek M, Grundy SM, et al.
HDL cholesterol, very low levels of LDL
cholesterol, and cardiovascular events.
New England Journal of Medicine. 2007;
357(13):1301-1310
[42] Kapoor D, Malkin CJ, Channer KS,
Jones TH. Androgens, insulin resistance
and vascular disease in men. Clinical
Endocrinology. 2005;63(3):239-250
15
Role of Androgens in Cardiovascular Diseases in Men: A Comprehensive Review
DOI: http://dx.doi.org/10.5772/intechopen.85852
[43]Nielsen TL, Hagen C, Wraae K,
Brixen K, Petersen PH, Haug E, et al.
Visceral and subcutaneous adipose
tissue assessed by magnetic resonance
imaging in relation to circulating
androgens, sex hormone-binding
globulin, and luteinizing hormone in
young men. The Journal of Clinical
Endocrinology & Metabolism. 2007;
92(7):2696-2705
[44] Rader DJ. High-density lipoproteins
and atherosclerosis. The American
Journal of Cardiology. 2002;90(8):62-70
[45] Zannis VI, Kypreos KE, Chroni A,
Kardassis D, Zanni EE. Lipoproteins and
atherogenesis. Molecular Mechanisms of
Atherosclerosis. 2004;8:111-174
[46] Liu B, Krieger M. Highly purified
scavenger receptor class B, type I
reconstituted into phosphatidylcholine/
cholesterol liposomes mediates high
affinity high density lipoprotein binding
and selective lipid uptake. Journal of
Biological Chemistry. 2002;277(37):
34125-34135
[47] Isidori AM, Giannetta E, Greco EA,
Gianfrilli D, Bonifacio V, Isidori A, et al.
Effects of testosterone on body
composition, bone metabolism and
serum lipid profile in middle-aged men:
A meta-analysis. Clinical Endocrinology.
2005;63(3):280-293
[48]Haring R, Baumeister SE, Völzke H,
Dörr M, Felix SB, Kroemer HK, et al.
Prospective association of low total
testosterone concentrations with an
adverse lipid profile and increased
incident dyslipidemia. European Journal
of Cardiovascular Prevention &
Rehabilitation. 2011;18(1):86-96
[49] Beigneux AP, Franssen R,
Bensadoun A, Gin P, Melford K, Peter J,
et al. Chylomicronemia with a mutant
GPIHBP1 (Q115P) that cannot bind
lipoprotein lipase. Arteriosclerosis,
Thrombosis, and Vascular Biology.
2009;29(6):956-962
[50] Langer C, Gansz B, Goepfert C,
Engel T, Uehara Y, von Dehn G, et al.
Testosterone up-regulates scavenger
receptor BI and stimulates cholesterol




[51]Wiinberg N, Høegholm A,
Christensen HR, Bang LE,
Mikkelsen KL, Nielsen PE, et al. 24-h
ambulatory blood pressure in 352
normal Danish subjects, related to age
and gender. American Journal of
Hypertension. 1995;8(10):978-986
[52] Egan BM, Zhao Y, Axon RN. US
trends in prevalence, awareness,
treatment, and control of hypertension,
1988-2008. JAMA. 2010;303(20):
2043-2050
[53]Himmelmann A, Svensson A,
Hansson L. Influence of sex on blood
pressure and left ventricular mass in
adolescents: The Hypertension in
Pregnancy Offspring Study. Journal of
Human Hypertension. 1994;8(7):
485-490
[54] Burt VL, Whelton P, Roccella EJ,
Brown C, Cutler JA, Higgins M, et al.
Prevalence of hypertension in the US
adult population: Results from the Third
National Health and Nutrition
Examination Survey, 1988-1991.
Hypertension. 1995;25(3):305-313
[55]Wilson C, Maass R, Estrada M.
Cardiovascular effects of androgens. In:
Akin F, editor. Basic and Clinical






[56] Stamler J, Stamler R, Riedlinger WF,
Algera G, Roberts RH. Hypertension
screening of 1 million Americans:
Community hypertension evaluation
16
Chemistry and Biological Activity of Steroids
clinic (CHEC) program, 1973 through
1975. JAMA. 1976;235(21):2299-2306
[57] Kienitz T, Quinkler M. Testosterone
and blood pressure regulation. Kidney
and Blood Pressure Research. 2008;
31(2):71-79
[58] Suzuki H, Tominaga T, Kumagai H,
Saruta T. Effects of first-line
antihypertensive agents on sexual
function and sex hormones. Journal of
Hypertension. Supplement: Official
Journal of the International Society of
Hypertension. 1988;6(4):S649-S651
[59] Fogari R, Corradi L, Marasi G,
Zoppi A, Mugellini A, Banderali A, et al.
I007: Sexual activity and testosterone
levels in hypertensive males. American
Journal of Hypertension. 2000;13(S2):
278A
[60] Tangredi JF, Buxton IL.
Hypertension as a complication of
topical testosterone therapy. Annals of
Pharmacotherapy. 2001;35(10):
1205-1207
[61] Reckelhoff JF, Yanes LL, Iliescu R,
Fortepiani LA, Granger JP. Testosterone
supplementation in aging men and
women: Possible impact on
cardiovascular-renal disease. American
Journal of Physiology-Renal Physiology.
2005;289(5):F941-F948
[62] Cheung KK, Luk AO, So WY,
Ma RC, Kong AP, Chow FC, et al.
Testosterone level in men with type 2
diabetes mellitus and related metabolic
effects: A review of current evidence.
Journal of Diabetes Investigation. 2015;
6(2):112-123
[63] Fogari R, Preti P, Zoppi A, Fogari E,
Rinaldi A, Corradi L, et al. Serum
testosterone levels and arterial blood
pressure in the elderly. Hypertension
Research. 2005;28(8):625-630
[64] Reckelhoff JF, Granger JP. Role of
androgens in mediating hypertension
and renal injury. Clinical and
Experimental Pharmacology and
Physiology. 1999;26(2):127-131
[65]Dubey RK, Oparil S, Imthurn B,
Jackson EK. Sex hormones and
hypertension. Cardiovascular Research.
2002;53(3):688-708
[66] Ely DL, Salisbury R, Hadi D,
Turner M, Johnson ML. Androgen
receptor and the testes influence
hypertension in a hybrid rat model.
Hypertension. 1991;17:1104-1110
[67]Wang C, Nieschlag E, Swerdloff R,
Behre HM, HellstromWJ, Gooren LJ,
et al. Investigation, treatment, and
monitoring of late-onset hypogonadism
in males: ISA, ISSAM, EAU, EAA, and
ASA recommendations. European Journal
of Endocrinology. 2008;159(5):507-514
[68] Lin TH, Yeh S, Chang C. Tissue-
specific knockout of androgen receptor
in mice. In: Androgen Action. Totowa,
New Jersey, USA: Humana Press; 2011.
pp. 275-293
[69] Rhoden EL, Ribeiro EP, Teloken C,
Souto CA. Diabetes mellitus is
associated with subnormal serum levels
of free testosterone in men. BJU
International. 2005;96(6):867-870
[70] Selvin E, Feinleib M, Zhang L,
Rohrmann S, Rifai N, Nelson WG, et al.
Androgens and diabetes in men: Results
from the Third National Health and
Nutrition Examination Survey
(NHANES III). Diabetes Care. 2007;
30(2):234-238
[71] Colangelo LA, Ouyang P, Liu K,
Kopp P, Golden SH, Dobs AS, et al.
Association of endogenous sex
hormones with diabetes and impaired
fasting glucose in men: The Multi-
Ethnic Study of Atherosclerosis.
Diabetes Care. 2009;32(6):1049-1051
[72] Corona G, Monami M, Rastrelli G,
Aversa A, Sforza A, Lenzi A, et al.
17
Role of Androgens in Cardiovascular Diseases in Men: A Comprehensive Review
DOI: http://dx.doi.org/10.5772/intechopen.85852
Type 2 diabetes mellitus and
testosterone: A meta-analysis study.
International Journal of Andrology.
2011;34:528-540
[73]Ding EL, Song Y, Malik VS, Liu S.
Sex differences of endogenous sex
hormones and risk of type 2 diabetes: A
systematic review and meta-analysis.
JAMA. 2006;295(11):1288-1299
[74]DeFronzo RA. Insulin resistance,
lipotoxicity, type 2 diabetes and
atherosclerosis: The missing links. The
Claude Bernard Lecture 2009.
Diabetologia. 2010;53(7):1270-1287
[75]Mlinar B, Marc J, Janež A, Pfeifer M.
Molecular mechanisms of insulin
resistance and associated diseases. Clinica
Chimica Acta. 2007;375(1-2):20-35
[76]Grossmann M, Gianatti EJ, Zajac JD.
Testosterone and type 2 diabetes.
Current Opinion in Endocrinology,
Diabetes and Obesity. 2010;17(3):
247-256
[77] Pitteloud N, Hardin M, Dwyer AA,
Valassi E, Yialamas M, Elahi D, et al.
Increasing insulin resistance is
associated with a decrease in Leydig cell
testosterone secretion in men. The
Journal of Clinical Endocrinology &
Metabolism. 2005;90(5):2636-2641
[78]Osuna CJA, Gomez-Perez R, Arata-
Bellabarba G, Villaroel V. Relationship
between BMI, total testosterone, sex
hormone-binding-globulin, leptin,
insulin and insulin resistance in obese
men. Archives of Andrology. 2006;
52(5):355-361
[79] Cook NL, Romashkan S. Why do we
need a trial on the effects of testosterone
therapy in older men? Clinical
Pharmacology & Therapeutics. 2011;
89(1):29-31
[80] Bhasin S, Jasjua GK, Pencina M,
D’agostino R, Coviello AD, Vasan RS,
et al. Sex hormone–binding globulin,
but not testosterone, is associated
prospectively and independently with
incident metabolic syndrome in men:
The Framingham Heart Study. Diabetes
Care. 2011;34(11):2664-2670
[81] Yeap BB, Araujo AB, Wittert GA.
Do low testosterone levels contribute to
ill-health during male ageing? Critical
Reviews in Clinical Laboratory Sciences.
2012;49(5-6):168-182
[82]Dhindsa S, Prabhakar S, Sethi M,
Bandyopadhyay A, Chaudhuri A,
Dandona P. Frequent occurrence of
hypogonadotropic hypogonadism in
type 2 diabetes. The Journal of Clinical
Endocrinology & Metabolism. 2004;
89(11):5462-5468
[83] Kapoor D, Clarke S, Stanworth R,
Channer KS, Jones TH. The effect of
testosterone replacement therapy on
adipocytokines and C-reactive protein
in hypogonadal men with type 2
diabetes. European Journal of
Endocrinology. 2007;156(5):595-602
[84] Grossmann M, Thomas MC,
Panagiotopoulos S, Sharpe K,
MacIsaac RJ, Clarke S, et al. Low
testosterone levels are common and
associated with insulin resistance in men
with diabetes. The Journal of Clinical
Endocrinology & Metabolism. 2008;
93(5):1834-1840





[86] Isfort M, Stevens SC, Schaffer S,
Jong CJ, Wold LE. Metabolic
dysfunction in diabetic
cardiomyopathy. Heart Failure Reviews.
2014;19(1):35-48
[87]Dhalla NS, Takeda N, Rodriguez-
Leyva D, Elimban V. Mechanisms of
subcellular remodeling in heart failure
18
Chemistry and Biological Activity of Steroids
due to diabetes. Heart Failure Reviews.
2014;19(1):87-99
[88]Muthusamy T, Murugesan P,
Balasubramanian K. Sex steroids
deficiency impairs glucose transporter 4
expression and its translocation through
defective Akt phosphorylation in target
tissues of adult male rat. Metabolism.
2009;58(11):1581-1592
[89] Xia F, Xu X, Zhai H, Meng Y,
Zhang H, Du S, et al. Castration-induced
testosterone deficiency increases fasting
glucose associated with hepatic and
extra-hepatic insulin resistance in adult
male rats. Reproductive Biology and
Endocrinology. 2013;11(1): Article No.
106
[90] Chen X, Li X, Huang HY, Lin JF.
Effects of testosterone on insulin
receptor substrate-1 and glucose
transporter 4 expression in cells
sensitive to insulin. Zhonghua Yi Xue Za
Zhi. 2006;86(21):1474-1477
[91] Sato K, Iemitsu M, Aizawa K,
Ajisaka R. Testosterone and DHEA
activate the glucose metabolism-related
signaling pathway in skeletal muscle.
American Journal of Physiology-
Endocrinology and Metabolism. 2008;
294(5):E961-E968
[92] Kelly DM, Jones TH. Testosterone:
A metabolic hormone in health and
disease. Journal of Endocrinology. 2013;
217:R25-R45
[93] Palomar-Morales M, Morimoto S,
Mendoza-Rodríguez CA, Cerbón MA.
The protective effect of testosterone on
streptozotocin-induced apoptosis in β
cells is sex specific. Pancreas. 2010;
39(2):193-200
[94]McInnes KJ, Smith LB, Hunger NI,
Saunders PT, Andrew R, Walker BR.
Deletion of the androgen receptor in
adipose tissue in male mice elevates
retinol binding protein 4 and reveals
independent effects on visceral fat mass
and on glucose homeostasis. Diabetes.
2012;61(5):1072-1081
[95] Pugh PJ, English KM, Jones TH,
Channer KS. Testosterone: A natural
tonic for the failing heart? QJM. 2000;
93(10):689-694
[96] Kelly DM, Jones TH. Testosterone:
A vascular hormone in health and
disease. Journal of Endocrinology. 2013;
217:R47-R71
[97] Yang Q, Graham TE, Mody N,
Preitner F, Peroni OD, Zabolotny JM,
et al. Serum retinol binding protein 4
contributes to insulin resistance in
obesity and type 2 diabetes. Nature.
2005;436(7049):356-362
[98]Maggio M, Basaria S, Ble A,
Lauretani F, Bandinelli S, Ceda GP, et al.
Correlation between testosterone and
the inflammatory marker soluble
interleukin-6 receptor in older men. The
Journal of Clinical Endocrinology &
Metabolism. 2006;91(1):345-347
[99]Nettleship JE, Pugh PJ, Channer KS,
Jones T, Jones RD. Inverse relationship
between serum levels of interleukin-1β
and testosterone in men with stable
coronary artery disease. Hormone and
Metabolic Research. 2007;39(05):
366-371
[100]Watkins LR, Hutchinson MR,
Johnston IN, Maier SF. Glia: Novel
counter-regulators of opioid analgesia.
Trends in Neurosciences. 2005;28(12):
661-669
[101]Malkin CJ, Pugh PJ, Jones RD,
Kapoor D, Channer KS, Jones TH. The
effect of testosterone replacement on
endogenous inflammatory cytokines
and lipid profiles in hypogonadal men.
The Journal of Clinical Endocrinology &
Metabolism. 2004;89(7):3313-3318
[102]Malkin CJ, Pugh PJ, Morris PD,
Kerry KE, Jones RD, Jones TH, et al.
Testosterone replacement in
19
Role of Androgens in Cardiovascular Diseases in Men: A Comprehensive Review
DOI: http://dx.doi.org/10.5772/intechopen.85852
hypogonadal men with angina improves
ischemic threshold and quality of life.
Heart. 2004;90(8):871-876
[103]Haider A, Gooren LJ, Padungtod P,
Saad F. Improvement of the metabolic
syndrome and of non-alcoholic liver
steatosis upon treatment of
hypogonadal elderly men with
parenteral testosterone undecanoate.
Experimental and Clinical
Endocrinology & Diabetes. 2010;
118(03):167-171
[104]Nathan L, Shi W, Dinh H,
Mukherjee TK, Wang X, Lusis AJ, et al.
Testosterone inhibits early
atherogenesis by conversion to estradiol:
Critical role of aromatase. Proceedings
of the National Academy of Sciences.
2001;98(6):3589-3593
[105]Hougaku H, Fleg JL, Najjar SS,
Lakatta EG, Harman SM, Blackman MR,
et al. Relationship between androgenic
hormones and arterial stiffness, based
on longitudinal hormone
measurements. American Journal of
Physiology-Endocrinology and
Metabolism. 2006;290(2):E234-E242
[106]Mäkinen J, Järvisalo MJ,
Pöllänen P, Perheentupa A, Irjala K,
Koskenvuo M, et al. Increased carotid
atherosclerosis in andropausal middle-
aged men. Journal of the American
College of Cardiology. 2005;45(10):
1603-1608
[107] Vikan T, Johnsen SH, Schirmer H,
Njølstad I, Svartberg J. Endogenous
testosterone and the prospective
association with carotid atherosclerosis
in men: The Tromsø study. European
Journal of Epidemiology. 2009;24(6):
289-295
[108] Van den Beld AW, Bots ML,
Janssen JA, Pols HA, Lamberts SW,
Grobbee DE. Endogenous hormones and
carotid atherosclerosis in elderly men.
American Journal of Epidemiology.
2003;157(1):25-31
[109] Fukui M, Kitagawa Y, Ose H,
Hasegawa G, Yoshikawa T,
Nakamura N. Role of endogenous
androgen against insulin resistance and
athero-sclerosis in men with type 2
diabetes. Current Diabetes Reviews.
2007;3(1):25-31
[110] Fu L, Gao QP, Shen JX.
Relationship between testosterone and
indexes indicating endothelial function
in male coronary heart disease patients.
Asian Journal of Andrology. 2008;10(2):
214-218
[111]Mathur A, Malkin C, Saeed B,
Muthusamy R, Jones TH, Channer K.
Long-term benefits of testosterone
replacement therapy on angina
threshold and atheroma in men.
European Journal of Endocrinology.
2009;161(3):443-449
[112] Zitzmann M, Vorona E, Wenk M,
Saad F, Nieschlag E. Testosterone
administration decreases carotid artery
intima media thickness as a marker of
impaired vascular integrity in middle-
aged overweight men: 61. Journal of
Men's Health. 2009;6(3):243
[113] von Eckardstein A, Wu FC.
Testosterone and atherosclerosis.
Growth Hormone & IGF Research.
2003;13:S72-S84
[114] Lu YL, Kuang L, Zhu H, Wu H,
Wang XF, Pang YP, et al. Changes in
aortic endothelium ultrastructure in
male rats following castration,
replacement with testosterone and
administration of 5α-reductase
inhibitor. Asian Journal of Andrology.
2007;9(6):843-847
[115]Miller VM, Mulvagh SL. Sex
steroids and endothelial function:
Translating basic science to clinical
practice. Trends in Pharmacological
Sciences. 2007;28(6):263-270
[116] Foresta C, Zuccarello D, De Toni L,
Garolla A, Caretta N, Ferlin A.
20
Chemistry and Biological Activity of Steroids
Androgens stimulate endothelial
progenitor cells through an androgen
receptor-mediated pathway. Clinical
Endocrinology. 2008;68(2):284-289
[117]Ong PJ, Patrizi G, Chong WC,
Webb CM, Hayward CS, Collins P.
Testosterone enhances flow-mediated
brachial artery reactivity in men with
coronary artery disease. American
Journal of Cardiology. 2000;85(2):
269-272
[118] Akishita M, Hashimoto M,
Ohike Y, Ogawa S, Iijima K, Eto M, et al.
Low testosterone level is an
independent determinant of endothelial
dysfunction in men. Hypertension
Research. 2007;30(11):1029-1034
[119] Rubio-Gayosso I, Garcia-Ramirez
O, Gutierrez-Serdan R, Guevara-
Balcazar G, Muñoz-Garcı ́a O, Morato-
Cartajena T, et al. Testosterone inhibits
bradykinin-induced intracellular
calcium kinetics in rat aortic endothelial
cells in culture. Steroids. 2002;67(5):
393-397
[120]Wu FC, von Eckardstein A.
Androgens and coronary artery disease.
Endocrine Reviews. 2003;24(2):183-217
[121] Traish AM. Adverse health effects
of testosterone deficiency (TD) in men.
Steroids. 2014;88:106-116
[122]Neyses L, Pelzer T. The biological
cascade leading to cardiac hypertrophy.
European Heart Journal. 1995;16:8-11
[123]Maron BJ, Epstein SE.
Hypertrophic cardiomyopathy: Recent
observations regarding the specificity of
three hallmarks of the disease:
Asymmetric septal hypertrophy, septal
disorganization and systolic anterior
motion of the anterior mitral leaflet. The
American Journal of Cardiology. 1980;
45(1):141-154
[124] Levy D, Garrison RJ, Savage DD,
Kannel WB, Castelli WP. Prognostic
implications of echocardiographically
determined left ventricular mass in the
Framingham Heart Study. New England
Journal of Medicine. 1990;322(22):
1561-1566
[125]Hayward CS, Webb CM, Collins P.
Effect of sex hormones on cardiac mass.
The Lancet. 2001;357(9265):1354-1356
[126] Svartberg J, von Muhlen D,
Schirmer H, Barrett-Connor E,
Sundfjord J, Jorde R. Association of
endogenous testosterone with blood
pressure and left ventricular mass in
men. The Tromso Study. European
Journal of Endocrinology. 2004;150(1):
65-71
[127] Pirompol P, Teekabut V,
Weerachatayanukul W, Bupha-Intr T.
Supra-physiological dose of testosterone
induces pathological cardiac
hypertrophy. Journal of Endocrinology.
2016;229:13-23
[128]Miyazaki M, Esser KA. Cellular
mechanisms regulating protein
synthesis and skeletal muscle
hypertrophy in animals. Journal of
Applied Physiology. 2009;106(4):
1367-1373
[129] Fry CS, Drummond MJ, Glynn EL,
Dickinson JM, Gundermann DM,
Timmerman KL, et al. Aging impairs
contraction-induced human skeletal
muscle mTORC1 signaling and protein
synthesis. Skeletal Muscle. 2011;1(1):11
[130] Altamirano F, Oyarce C, Silva P,
Toyos M, Wilson C, Lavandero S, et al.
Testosterone induces cardiomyocyte
hypertrophy through mammalian target
of rapamycin complex 1 pathway.
Journal of Endocrinology. 2009;202(2):
299-307
[131] Sinha-Hikim I, Cornford M,
Gaytan H, Lee ML, Bhasin S. Effects of
testosterone supplementation on
skeletal muscle fiber hypertrophy and
satellite cells in community-dwelling
21
Role of Androgens in Cardiovascular Diseases in Men: A Comprehensive Review
DOI: http://dx.doi.org/10.5772/intechopen.85852
older men. The Journal of Clinical
Endocrinology & Metabolism. 2006;
91(8):3024-3033
[132] Favier FB, Benoit H, Freyssenet D.
Cellular and molecular events
controlling skeletal muscle mass in
response to altered use. Pflügers Archiv-
European Journal of Physiology. 2008;
456(3):587-600
[133] Sinha-Hikim I, Artaza J,
Woodhouse L, Gonzalez-Cadavid N,
Singh AB, Lee MI, et al. Testosterone-
induced increase in muscle size in
healthy young men is associated with




[134] Kadi F. Cellular and molecular
mechanisms responsible for the action
of testosterone on human skeletal
muscle. A basis for illegal performance
enhancement. British Journal of
Pharmacology. 2008;154(3):522-528
[135] Estrada M, Espinosa A, Müller M,
Jaimovich E. Testosterone stimulates
intracellular calcium release and
mitogen-activated protein kinases via a
G protein-coupled receptor in skeletal
muscle cells. Endocrinology. 2003;
144(8):3586-3597
[136] Fu R, Liu J, Fan J, Li R, Li D, Yin J,
et al. Novel evidence that testosterone
promotes cell proliferation and
differentiation via G protein-coupled
receptors in the rat L6 skeletal muscle
myoblast cell line. Journal of Cellular
Physiology. 2012;227(1):98-107
[137] Tsitouras PD, Martin CE,
Harman SM. Relationship of serum
testosterone to sexual activity in healthy
elderly men. Journal of Gerontology.
1982;37(3):288-293
[138] Schweiger U, Deuschle M,
Weber B, Korner A, Lammers CH,
Schmider J, et al. Testosterone,
gonadotropin, and cortisol secretion in
male patients with major depression.
Psychosomatic Medicine. 1999;61:
292-296
[139] Stepan JJ, Lachman M, Zvěřina J,
Pacovský V, Baylink DJ. Castrated men
exhibit bone loss: Effect of calcitonin
treatment on biochemical indices of
bone remodeling. The Journal of Clinical
Endocrinology & Metabolism. 1999;
69(3):523-527
[140] Baumgartner RN, Waters DL,
Gallagher D, Morley JE, Garry PJ.
Predictors of skeletal muscle mass in
elderly men and women. Mechanisms of
Ageing and Development. 1999;107(2):
123-136
[141] Calof OM, Singh AB, Lee ML,
Kenny AM, Urban RJ, Tenover JL, et al.
Adverse events associated with
testosterone replacement in middle-
aged and older men: A meta-analysis of
randomized, placebo-controlled trials.
The Journals of Gerontology Series A:
Biological Sciences and Medical
Sciences. 2005;60(11):1451-1457
[142]Haddad RM, Kennedy CC,
Caples SM, Tracz MJ, Boloña ER,
Sideras K, et al. Testosterone and
cardiovascular risk in men: A systematic
review and meta-analysis of randomized
placebo-controlled trials. Mayo Clinic
Proceedings. 2007;82(1):29-39
[143] Fernández-Balsells MM,
Murad MH, Lane M, Lampropulos JF,
Albuquerque F, Mullan RJ, et al.
Adverse effects of testosterone therapy
in adult men: A systematic review and
meta-analysis. The Journal of Clinical
Endocrinology & Metabolism. 2010;
95(6):2560-2575
[144] Vigen R, O’Donnell CI, Barón AE,
Grunwald GK, Maddox TM,
Bradley SM, et al. Association of
testosterone therapy with mortality,
myocardial infarction, and stroke in
men with low testosterone levels. JAMA.
2013;310(17):1829-1836
22
Chemistry and Biological Activity of Steroids
[145] Sharma R, Oni OA, Chen G,
Sharma M, Dawn B, Sharma R, et al.
Association between testosterone
replacement therapy and the incidence
of DVT and Pulmonary embolism: A
retrospective cohort study of the
veterans administration database. Chest.
2016;150(3):563-571
[146] European Medicines Agency. No
consistent evidence of an increased risk
of heart problems with testosterone





[147] Alexander GC, Iyer G, Lucas E,
Lin D, Singh S. Cardiovascular risks of
exogenous testosterone use among men:
A systematic review and meta-analysis.
The American Journal of Medicine.
2017;130(3):293-305
[148] Loo SY, Chen BY, Yu OHY,
Azoulay L, Renoux C. Testosterone
replacement therapy and the risk of
stroke in men: A systematic review.
Maturitas. 2017;106:31-37
[149] Shores MM, Smith NL,
Forsberg CW, Anawalt BD,
Matsumoto AM. Testosterone treatment
and mortality in men with low
testosterone levels. The Journal of
Clinical Endocrinology & Metabolism.
2012;97(6):2050-2058
[150]Muraleedharan V, Ranjan N,
Rolfe C, Jones TH. The effect of
testosterone undecanoate on
cardiovascular risk factors in men with
hypogonadism in clinical practice.
Endocrine Reviews. 2010;31(3). Issue 3
Supplement
[151] Bagatell CJ, Heiman JR,
Matsumoto AM, Rivier JE, Bremner WJ.
Metabolic and behavioral effects of
high-dose, exogenous testosterone in
healthy men. The Journal of Clinical
Endocrinology & Metabolism. 1994;
79(2):561-567
[152] Kapoor D, Goodwin E,
Channer KS, Jones TH. Testosterone
replacement therapy improves insulin
resistance, glycaemic control, visceral
adiposity and hypercholesterolaemia in
hypogonadal men with type 2 diabetes.
European Journal of Endocrinology.
2006;154(6):899-906
[153] Zitzmann M, Nieschlag E.
Androgen receptor gene CAG repeat
length and body mass index modulate
the safety of long-term intramuscular
testosterone undecanoate therapy in
hypogonadal men. The Journal of
Clinical Endocrinology & Metabolism.
2007;92(10):3844-3853
[154] Zhang KS, Zhao MJ, An Q, Jia YF,
Fu LL, Xu JF, et al. Effects of
testosterone supplementation therapy
on lipid metabolism in hypogonadal
men with T2 DM: A meta-analysis of
randomized controlled trials.
Andrology. 2018;6(1):37-46
[155] Corona G, Rastrelli G, Di
Pasquale G, Sforza A, Mannucci E,
Maggi M. Testosterone and
cardiovascular risk: Meta-analysis of
interventional studies. The Journal of
Sexual Medicine. 2018;15(6):820-838
[156] Finkle WD, Greenland S,
Ridgeway GK, Adams JL, Frasco MA,
Cook MB, et al. Increased risk of non-
fatal myocardial infarction following
testosterone therapy prescription in
men. PloS One. 2014;9(1):e85805
[157] Basaria S, Coviello AD,
Travison TG, Storer TW, Farwell WR,
Jette AM, et al. Adverse events
associated with testosterone
administration. New England Journal of
Medicine. 2010;363(2):109-122
[158] Xu L, Freeman G, Cowling BJ,
Schooling CM. Testosterone therapy
and cardiovascular events among men:
A systematic review and meta-analysis
of placebo-controlled randomized trials.
BMC Medicine. 2013;11(1):108
23
Role of Androgens in Cardiovascular Diseases in Men: A Comprehensive Review
DOI: http://dx.doi.org/10.5772/intechopen.85852
[159] Bouchardy B, Majno G.
Histopathology of early myocardial
infarcts: A new approach. The American
Journal of Pathology. 1974;74(2):301
[160] Knowlton KU, Chien KR.
Inflammatory pathways and cardiac
repair: The affliction of infarction.
Nature Medicine. 1999;5(10):1122
[161] Cavasin MA, Sankey SS, Yu AL,
Menon S, Yang XP. Estrogen and
testosterone have opposing effects on
chronic cardiac remodeling and
function in mice with myocardial




Chemistry and Biological Activity of Steroids
